NEW YORK (

TheStreet

) -- Shares of

Progenics Pharmaceuticals

(Nasdaq:

PGNX

) have taken a tremendous swing upward. The stock is trading at $6.72 as of 4 p.m. ET, 20.9% above Tuesday's closing price of $5.56. Volume is at 276,304, 2.5 times the daily average of 111,300.

Progenics has a market cap of $169.8 million and is part of the

health care

sector and

drugs

industry. Shares are up 1.8% year to date as of the close of trading on Tuesday.

Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases in the United States and internationally. The company has a P/E ratio of 91.7, below the average drugs industry P/E ratio of 125.8 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Progenics as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. You can view the full

Progenics Ratings Report

.

See our

top % gaining stocks list

for other stocks that are soaring today, or get investment ideas from our

investment research center

.

Interested in other stocks that are soaring? Get free SMS text alerts sent to you when the action happens by texting

SOAR

to 95370 or select from

multiple alert options

.

null